Therefore, because of the correlation with smoking history, we suggest that KRAS‐mutant NSCLC may express a higher level of PD‐L1 protein and TMB compared with wild‐type tumors, which may reflect the efficacy of immune checkpoint inhibitors (ICIs) against PD‐1/PD‐L1. This evidence concerns the gene KRAS and non-small cell lung carcinoma.